High-throughput intracellular antimicrobial susceptibility testing of Legionella pneumophila

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7517-7529

  Chiaraviglio, Lucius ^a   Kirby, James E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FLORFENICOL; FLUMEQUINE; FUSIDIC ACID; GATIFLOXACIN; GENTAMICIN; JOSAMYCIN; KANAMYCIN; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; MITOMYCIN; MOXIFLOXACIN; PEFLOXACIN; RIFAMPICIN; ROXITHROMYCIN; TETRACYCLINE; TIGECYCLINE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM; FLUORESCENT DYE; MACROLIDE; ORGANIC COMPOUND; QUINOLONE DERIVATIVE; SYTOX GREEN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; CELL DEATH; CLINICAL OBSERVATION; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DILUTION; DOSE RESPONSE; DRUG EFFICACY; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; IC50; LEGIONELLA PNEUMOPHILA; LUMINESCENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPERON; PRIORITY JOURNAL; CELL LINE; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; LUNG ALVEOLUS MACROPHAGE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLUORESCENT DYES; FLUOROQUINOLONES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LEGIONELLA PNEUMOPHILA; MACROLIDES; MACROPHAGES, ALVEOLAR; MICROBIAL SENSITIVITY TESTS; ORGANIC CHEMICALS; TETRACYCLINES;

EID: 84954519784     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01248-15     Document Type: Article

References (61)

1. Kirby JE. 2015. Legionella and Bartonella. Reference module in biomedical sciences. Elsevier, New York, NY. http://dx.doi.org/10.1016/B978-0-12-801238-3.02296-0.
2. Vogel JP, Isberg RR. 1999. Cell biology of Legionella pneumophila. Curr Opin Microbiol 2:30-34. http://dx.doi.org/10.1016/S1369-5274(99)80005-8.
3. Catrenich CE, Johnson W. 1989. Characterization of the selective inhibition of growth of virulent Legionella pneumophila by supplemented Mueller-Hinton medium. Infect Immun 57:1862-1864.
4. Gerber JE, Casey CA, Martin P, Winn WC, Jr. 1981. Legionnaires' disease in Vermont, 1972-1976. Am J Clin Pathol 76:816-818.
5. Edelstein PH. 1995. Antimicrobial chemotherapy for Legionnaires' disease: a review. Clin Infect Dis 21(Suppl 3):S265-S276. http://dx.doi.org /10.1093/clind/21.Supplement-3.S265.
6. Edelstein PH, Meyer RD. 1980. Susceptibility of Legionella pneumophila to twenty antimicrobial agents. Antimicrob Agents Chemother 18:403-408. http://dx.doi.org/10.1128/AAC.18.3.403.
7. Pedro-Botet L, Yu VL. 2006. Legionella: macrolides or quinolones? Clin Microbiol Infect 12(Suppl 3):25-30.
8. Coers J, Vance RE, Fontana MF, Dietrich WF. 2007. Restriction of Legionella pneumophila growth in macrophages requires the concerted action of cytokine and Naip5/Ipaf signalling pathways. Cell Microbiol 9:2344-2357. http://dx.doi.org/10.1111/j.1462-5822.2007.00963.x.
9. Rao C, Benhabib H, Ensminger AW. 2013. Phylogenetic reconstruction of the Legionella pneumophila Philadelphia-1 laboratory strains through comparative genomics. PLoS One 8:e64129. http://dx.doi.org/10.1371 /journal.pone.0064129.
10. Chiaraviglio L, Kirby JE. 2014. Evaluation of impermeant, DNA-binding dye fluorescence as a real-time readout of eukaryotic cell toxicity in a high throughput screening format. Assay Drug Dev Technol 12:219-228. http: //dx.doi.org/10.1089/adt.2014.577.
11. Ren T, Zamboni DS, Roy CR, Dietrich WF, Vance RE. 2006. Flagellindeficient Legionella mutants evade caspase-1-and Naip5-mediated macrophage immunity. PLoS Pathog 2:e18. http://dx.doi.org/10.1371/journal.ppat.0020018.
12. Reference deleted.
13. Elion GB, Singer S, Hitchings GH. 1954. Antagonists of Nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 208:477-488.
14. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1. http://dx.doi.org/10.1093 /jac/dkg301.
15. Yamano H, Yamazaki T, Sato K, Shiga S, Hagiwara T, Ouchi K, Kishimoto T. 2005. In vitro inhibitory effects of hinokitiol on proliferation of Chlamydia trachomatis. Antimicrob Agents Chemother 49:2519-2521. http://dx.doi.org/10.1128/AAC.49.6.2519-2521.2005.
16. Shih YH, Chang KW, Hsia SM, Yu CC, Fuh LJ, Chi TY, Shieh TM. 2013. In vitro antimicrobial and anticancer potential of hinokitiol against oral pathogens and oral cancer cell lines. Microbiol Res 168:254-262. http: //dx.doi.org/10.1016/j.micres.2012.12.007.
17. Morita Y, Matsumura E, Okabe T, Fukui T, Shibata M, Sugiura M, Ohe T, Tsujibo H, Ishida N, Inamori Y. 2004. Biological activity of alphathujaplicin, the isomer of hinokitiol. Biol Pharm Bull 27:899-902. http: //dx.doi.org/10.1248/bpb.27.899.
18. Berger KH, Isberg RR. 1993. Two distinct defects in intracellular growth complemented by a single genetic locus in Legionella pneumophila. Mol Microbiol 7:7-19. http://dx.doi.org/10.1111/j.1365-2958.1993.tb01092.x.
19. Berenbaum MC. 1978. A method for testing for synergy with any number of agents. J Infect Dis 137:122-130. http://dx.doi.org/10.1093/infdis/137.2.122.
20. Mills GD, Oehley MR, Arrol B. 2005. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 330: 456. http://dx.doi.org/10.1136/bmj.38334.591586.82.
21. Unertl, KE, Lenhart FP, Forst H, Vogler G, Wilm V, Ehret W, Ruckdeschel G. 1989. Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin.AmJ Med 87:128S-131S. http://dx.doi.org/10.1016/0002-9343(89)90041-7.
22. Kurz RW, Graninger W, Egger TP, Pichler H, Tragl KH. 1988. Failure of treatment of Legionella pneumonia with ciprofloxacin. J Antimicrob Chemother 22:389-391. http://dx.doi.org/10.1093/jac/22.3.389.
23. Miller AC. 1981. Erythromycin in Legionnaires' disease: a re-appraisal. J Antimicrob Chemother 7:217-222. http://dx.doi.org/10.1093/jac/7.3.217.
24. Hohl P, Buser U, Frei R. 1992. Fatal Legionella pneumophila pneumonia: treatment failure despite early sequential oral-parenteral amoxicillinclavulanic acid therapy. Infection 20:99-100. http://dx.doi.org/10.1007 /BF01711076.
25. Yoshida S, Mizuguchi Y, Ohta H, Ogawa M. 1985. Effects of tetracyclines on experimental Legionella pneumophila infection in guinea-pigs. J Antimicrob Chemother 16:199-204. http://dx.doi.org/10.1093/jac/16.2.199.
26. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG, Infectious Diseases Society of America, American Thoracic Society. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27-S72. http://dx.doi.org/10.1086/511159.
27. Ragnar Norrby S. 1997. Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group. J Antimicrob Chemother 39:499-508.
28. Bopp LH, Baltch AL, Ritz WJ, Michelsen PB, Smith RP. 2011. Activities of tigecycline and comparators against Legionella pneumophila and Legionella micdadei extracellularly and in human monocyte-derived macrophages. Diagn Microbiol Infect Dis 69:86-93. http://dx.doi.org/10.1016/j.diagmicrobio.2010.08.023.
29. Edelstein PH, Weiss WJ, Edelstein MA. 2003. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 47:533-540. http://dx.doi.org/10.1128/AAC.47.2.533-540.2003.
30. Friis-Moller A, Rechnitzer C, Nielsen L, Madsen S. 1985. Treatment of Legionella lung abscess in a renal transplant recipient with erythromycin and fusidic acid. Eur J Clin Microbiol 4:513-515. http://dx.doi.org/10.1007/BF02014439.
31. Yoshida S, Mizuguchi Y. 1984. Antibiotic susceptibility of Legionella pneumophila Philadelphia-1 in cultured guinea-pig peritoneal macrophages. J Gen Microbiol 130:901-906.
32. Gibson DH, Fitzgeorge RB. 1983. Persistence in serum and lungs of guinea pigs of erythromycin, gentamicin, chloramphenicol and rifampicin and their in-vitro activities against Legionella pneumophila. J Antimicrob Chemother 12:235-244. http://dx.doi.org/10.1093/jac/12.3.235.
33. Lattimer GL, Rhodes LV, III. 1978. Legionnaires' disease. Clinical findings and one-year follow-up. JAMA 240:1169-1171.
34. Ryerson GG, Lauwasser ME, Block AJ, Barnett BE, Shands JW, Jr. 1978. Legionnaires' disease. A sporadic case. Chest 73:113-115.
35. Cook AL, St Claire M, Sams R. 2004. Use of florfenicol in non-human primates. J Med Primatol 33:127-133. http://dx.doi.org/10.1111/j.1600-0684.2004.00063.x.
36. Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A. 2004. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev 28:519-542. http://dx.doi.org/10.1016/j.femsre.2004.04.001.
37. Ramadan A, Abd El-Aty AM. 2011. Pharmacokinetics and distribution of florfenicol in bronchial secretions of healthy and Pasteurella multocida infected calves. Pharm Anal Acta 2:2153-2435.
38. Buggy BP, Saravolatz LD. 1995. Treatment of Legionella pneumophila lung abscess with clindamycin. Clin Infect Dis 20:1158-1162. http://dx.doi.org/10.1093/clinids/20.5.1158.
39. Stout JE, Sens K, Mietzner S, Obman A, Yu VL. 2005. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int J Antimicrob Agents 25:302-307. http://dx.doi.org/10.1016/j.ijantimicag.2004.08.019.
40. Stout JE, Arnold B, Yu VL. 1998. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells. J Antimicrob Chemother 41:289-291. http://dx.doi.org/10.1093/jac/41.2.289.
41. Stout JE, Arnold B, Yu VL. 1998. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells. Diagn Microbiol Infect Dis 30:37-43. http://dx.doi.org/10.1016/S0732-8893(97)00174-0.
42. Baltch AL, Smith RP, Franke MA, Michelsen PB. 1998. Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila. Antimicrob Agents Chemother 42:3153-3156.
43. Descours G, Ginevra C, Ader F, Forey F, Lina G, Etienne J, Jarraud S. 2011. Rifampicin-macrolide synergy against Legionella pneumophila serogroup 1 in human macrophages using a quantitative real-time PCR assay. Int J Antimicrob Agents 38:188-189. http://dx.doi.org/10.1016/j.ijantimicag.2011.05.001.
44. Martin SJ, Pendland SL, Chen C, Schreckenberger P, Danziger LH. 1996. In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella. Antimicrob Agents Chemother 40:1419-1421.
45. Kirby JR. 2007. In vivo mutagenesis using EZ-Tn5. Methods Enzymol 421:17-21. http://dx.doi.org/10.1016/S0076-6879(06)21003-6.
46. Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O'Connell J. 2005. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 49:3903-3909. http://dx.doi.org/10.1128/AAC.49.9.3903-3909.2005.
47. Chiaraviglio L, Brown DA, Kirby JE. 2008. Infection of cultured human endothelial cells by Legionella pneumophila. PLoS One 3:e2012. http://dx.doi.org/10.1371/journal.pone.0002012.
48. Casson CN, Shin S. 2013. Inflammasome-mediated cell death in response to bacterial pathogens that access the host cell cytosol: lessons from Legionella pneumophila. Front Cell Infect Microbiol 3:111. http://dx.doi.org/10.3389/fcimb.2013.00111.
49. Horwitz MA, Silverstein SC. 1983. Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin. J Clin Invest 71:15-26. http://dx.doi.org/10.1172/JCI110744.
50. Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. 2003. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am 17:615-634. http://dx.doi.org/10.1016/S0891-5520(03)00066-7.
51. Garzoni C, Kelley WL. 2009. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol 17:59-65. http://dx.doi.org /10.1016/j.tim.2008.11.005.
52. Jordheim LP, Ben Larbi S, Fendrich O, Ducrot C, Bergeron E, Dumontet C, Freney J, Doleans-Jordheim A. 2012. Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin. Int J Antimicrob Agents 39:444-447. http://dx.doi.org/10.1016/j.ijantimicag.2012.01.019.
53. Sandrini MP, Shannon O, Clausen AR, Bjorck L, Piskur J. 2007. Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria. Antimicrob Agents Chemother 51:2726-2732. http: //dx.doi.org/10.1128/AAC.00081-07.
54. Sandrini MP, Clausen AR, On SL, Aarestrup FM, Munch-Petersen B, Piskur J. 2007. Nucleoside analogues are activated by bacterial deoxyribonucleoside kinases in a species-specific manner. J Antimicrob Chemother 60:510-520. http://dx.doi.org/10.1093/jac/dkm240.
55. Sun R, Wang L. 2013. Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs. BMC Microbiol 13:184. http://dx.doi.org/10.1186/1471-2180-13-184.
56. Sperber SJ, Feibusch EL, Damiani A, Weinstein MP. 1993. In vitro activities of nucleoside analog antiviral agents against salmonellae. Antimicrob Agents Chemother 37:106-110. http://dx.doi.org/10.1128/AAC.37.1.106.
57. Doleans-Jordheim A, Bergeron E, Bereyziat F, Ben-Larbi S, Dumitrescu O, Mazoyer MA, Morfin F, Dumontet C, Freney J, Jordheim LP. 2011. Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. Eur J Clin Microbiol Infect Dis 30:1249-1256. http://dx.doi.org/10.1007/s10096-011-1220-3.
58. CLSI. 2015. Performance standards for antimicrobial susceptibility testing: twenty-fifth informational supplement. CLSI document M100-25. Clinical and Laboratory Standards Institute, Wayne, PA.
59. EUCAST. 2015. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0, 2015. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
60. Karthein J, Spohr M, Traub WH. 1986. Josamycin: interpretation of inhibition zones with the Bauer-Kirby agar disk diffusion test as compared with erythromycin. Chemotherapy 32:336-343. http://dx.doi.org/10.1159/000238432.
61. Wyeth Pharmaceuticals, Inc. 2008. Tygacil (tigecycline) for injection. Package insert. NDA 21-821/S-016. Wyeth Pharmaceuticals, Inc, Madison, NJ. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009 /021821s016lbl.pdf.